CEO James Sapirstein, RPh, MBA, brings more than 30 years of pharmaceutical industry experience to ContraVir Pharmaceuticals Inc. His career began at Eli Lilly; he has also held positions with Hoffmann-LaRoche, Bristol Myers Squibb, Gilead Sciences, Serono Laboratorie, and the privately held firm Tobira Therapeutics. Before joining ContraVir, he was CEO of Alliqua Therapeutics at Alliqua Inc., where he helped lead the transformation of transdermal wound care and drug delivery technology into a premier wound care organization. He also developed the growth strategies for the organization and was responsible for several key licensing opportunities that led to an increased return on investment for all of the shareholders. Mr. Sapirstein holds board positions on Panther Biotechnology Inc., Cortex Pharmaceuticals Inc. and Clinical Supplies Management.